I have followed along this stock for a few years, since it was promoted by one of the longs here on another board, old dog.
It's been an interesting story, and a promising story, but a story none the less.
The recent story, now of a partnership is again promising, and I truly hope for those who are in the stock, and to those of us who hope for advances in medical science, for those patients who need ongoing imaging, including myself, will see the delivery of improved cardiac noninvasive diagnostic. I don't know if this technology is the one, but the Market , which represents physicians and hospitals, will make that decision if they finally start to buy this, and test it in large numbers in the clinic. I am focusing my research now on a few new promising upstarts in this area as it looks like there will be breakthroughs now in noninvasive imaging, with AI-it just may not be here,
It hasn't happened yet, for VPT, but maybe it will now.
If it does, that's great. Really, that's great and I do hope for the best.
That I haven't invested, yet, reflects my approach of being an evidence-based investor, and so while that may seem strange to some, I need to see facts-hard data to confirm stories. It's just the way I am. Fairytales are wonderful, but I can't bank my hard earned and needed money unless I have a verification of stories. The hard work of some of the storytellers here is something to see, but it falls on deaf ears to those that are moved only by data. That approach made me finaciallly independent, and has saved me from losing the capital pool I have. I am ready to deploy meaningful funds in thi =s area-and now it appears the race is on as a few upstarts are in play as well
Price action is wonderful, and it's nice to see for those that are down, I am sure, but this has come back up a little bit, and halfway to around $.60 where it peaked within a few years and some bought in
In any event, good luck, and I will sign off of this board until there is some material data, and will follow along with all of you if and when that happens. It will be interesting to see if the material data is followed with enough data to analyze, what the profitability, if any, will be. Software sales will be a different market and need to be meaningful sales for the higher margins to make sense.
There have been too many stories here-China, GE, Mayo, VMS 3,#+, now 4, patents, 40+ sales people, 1000s of leads, conferences.... Now its time to wait for sales and financials. So this stock has sucked up enough time and capital for many -the story has grown old, and I am signing off. For those that have sent along kindness for the research and those in the ether that were here and benefited from the analysis-I am glad you didnt lose money to the story tellers.
So I wish everyone a good holiday, and I hope that after a few years, that this will really start to happen now for the investors, but mostly for the patients.
G